The earnings call reflects a positive sentiment with strong initial sales of newly launched products and promising developments in the pipeline. While there are some uncertainties regarding market size and reimbursement, the overall outlook is optimistic due to financial stability and strategic advancements.

Company Guidance -

Q3 2025

During Syndax Pharmaceuticals' first quarter 2025 earnings call, the company provided guidance on its recent commercial and clinical progress. Syndax reported $20 million in net revenue from the first full quarter of the Revuforj launch and $13.6 million from its joint launch of Niktimvo with Incyte, totaling $34 million in net sales. The company highlighted its robust pipeline, including ongoing pivotal trials like EVOLV-2, which is enrolling patients for the first frontline trial of a menin inhibitor. Syndax is well-funded with $602.1 million in cash and equivalents and expects to reach profitability with anticipated revenue contributions from Revuforj and Niktimvo. Additionally, Syndax is actively pursuing the inclusion of Revuforj in clinical guidelines and anticipates an expedited review process for its supplemental new drug application (sNDA) for Revuforj, seeking FDA approval for additional indications.

Strong Product Launches

Syndax reported $20 million in Revuforj net revenue and $13.6 million in Niktimvo net revenue in the first quarter of 2025, indicating successful product launches and strong market reception.

Financial Stability

The company is well-funded with $602.1 million in cash and equivalents, and anticipates reaching profitability with current revenue streams.

Pipeline Progress

The initiation of the EVOLV-2 trial, a pivotal frontline trial of revumenib, marks significant advancement in the menin inhibitor program.

NCCN Guidelines Inclusion

Revuforj has been rapidly included in NCCN guidelines, with expectations for further inclusion in clinical guidelines for mutant mNPM1 AML treatment.

FDA sNDA Submission

A Supplemental New Drug Application for Revuforj has been submitted, seeking priority review for relapse or refractory mutant mNPM1 AML.

Syndax Pharmaceuticals (SNDX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SNDX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	- / -	-0.98	―	―	―
Aug 04, 2025	2025 (Q2)	-1.02 / -	-0.8	―	―	―
May 05, 2025	2025 (Q1)	-1.25 / -0.98	-0.85	-15.29% (-0.13)
Mar 03, 2025	2024 (Q4)	-0.84 / -1.10	-1	-10.00% (-0.10)
Nov 05, 2024	2024 (Q3)	-1.07 / -0.98	-0.73	-34.25% (-0.25)
Aug 01, 2024	2024 (Q2)	-0.91 / -0.80	-0.64	-25.00% (-0.16)
May 08, 2024	2024 (Q1)	-0.98 / -0.85	-0.59	-44.07% (-0.26)
Feb 27, 2024	2023 (Q4)	-0.97 / -1.00	-0.62	-61.29% (-0.38)
Nov 02, 2023	2023 (Q3)	-0.79 / -0.73	-0.58	-25.86% (-0.15)
Aug 03, 2023	2023 (Q2)	-0.72 / -0.64	-0.62	-3.23% (-0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SNDX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 05, 2025	$13.57	$10.64	-21.59%
Mar 03, 2025	$15.64	$15.48	-1.02%
Nov 05, 2024	$19.69	$21.35	+8.43%
Aug 01, 2024	$22.00	$21.04	-4.36%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Syndax Pharmaceuticals Inc (SNDX) report earnings?

Syndax Pharmaceuticals Inc (SNDX) is schdueled to report earning on Aug 04, 2025, After Close (Confirmed).

What is Syndax Pharmaceuticals Inc (SNDX) earnings time?

Syndax Pharmaceuticals Inc (SNDX) earnings time is at Aug 04, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SNDX EPS forecast?

SNDX EPS forecast for the fiscal quarter 2025 (Q2) is -1.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing